CA3003589C - Dendrimer compositions and methods for treatment of peroxisomal disorders and leukodystrophies - Google Patents
Dendrimer compositions and methods for treatment of peroxisomal disorders and leukodystrophies Download PDFInfo
- Publication number
- CA3003589C CA3003589C CA3003589A CA3003589A CA3003589C CA 3003589 C CA3003589 C CA 3003589C CA 3003589 A CA3003589 A CA 3003589A CA 3003589 A CA3003589 A CA 3003589A CA 3003589 C CA3003589 C CA 3003589C
- Authority
- CA
- Canada
- Prior art keywords
- dendrimer
- leukodystrophy
- dendrimers
- therapeutic agents
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/595—Polyamides, e.g. nylon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562248163P | 2015-10-29 | 2015-10-29 | |
| US62/248,163 | 2015-10-29 | ||
| PCT/US2016/059697 WO2017075580A1 (en) | 2015-10-29 | 2016-10-31 | Compositions and methods for treatment of peroxisomal disorders and leukodystrophies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3003589A1 CA3003589A1 (en) | 2017-05-04 |
| CA3003589C true CA3003589C (en) | 2021-12-07 |
Family
ID=57233968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3003589A Active CA3003589C (en) | 2015-10-29 | 2016-10-31 | Dendrimer compositions and methods for treatment of peroxisomal disorders and leukodystrophies |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20170119899A1 (https=) |
| EP (1) | EP3368088B1 (https=) |
| JP (2) | JP7088473B2 (https=) |
| CN (1) | CN108430514B (https=) |
| AU (1) | AU2016343855B2 (https=) |
| CA (1) | CA3003589C (https=) |
| WO (1) | WO2017075580A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2957721C (en) * | 2014-08-13 | 2021-04-13 | The Johns Hopkins University | Selective dendrimer delivery to brain tumors |
| AU2018258654B2 (en) | 2017-04-27 | 2022-01-06 | The Johns Hopkins University | Dendrimer compositions for use in angiography |
| WO2018208707A1 (en) * | 2017-05-08 | 2018-11-15 | Neurovia, Inc. | Methods and compositions for treating demyelinating diseases |
| EP3707193A1 (en) | 2017-11-10 | 2020-09-16 | The Johns Hopkins University | Dendrimer delivery system and methods of use thereof |
| WO2019118951A2 (en) * | 2017-12-15 | 2019-06-20 | Duke University | Compositions and methods of enhancing the homing and/or engraftment of hematopoietic cells in the central nervous system |
| US20220072019A1 (en) * | 2018-10-19 | 2022-03-10 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 in combination with nad+ or a nad+ precursor |
| WO2020142373A1 (en) * | 2019-01-02 | 2020-07-09 | Mayo Foundation For Medical Education And Research | Methods and materials for treating leukodystrophies |
| JP7759322B2 (ja) | 2019-12-04 | 2025-10-23 | アシュバッタ セラピューティクス, インコーポレイテッド | 眼に薬物送達するためのデンドリマー組成物および方法 |
| IL297531A (en) * | 2020-04-24 | 2022-12-01 | Ashvattha Therapeutics Inc | Dendrimer preparations and methods for treating severe acute respiratory distress syndrome |
| CA3189682A1 (en) * | 2020-07-17 | 2022-01-20 | Ashvattha Therapeutics, Inc. | Dendrimer compositions and methods for drug delivery to injured kidney |
| EP4426847A4 (en) * | 2021-11-04 | 2026-02-25 | Childrens Hospital Philadelphia | Compositions and methods for the treatment of metachromatic leukodystrophy and related disorders |
| US20260103728A1 (en) * | 2022-10-12 | 2026-04-16 | The Johns Hopkins University | Method of treating lbsl by enhancing dars2 expression |
| CN116082153A (zh) * | 2022-12-09 | 2023-05-09 | 长沙贝塔医药科技有限公司 | 一种丙烯酸酯类衍生物-13c的制备方法 |
| EP4410284A1 (en) * | 2023-02-02 | 2024-08-07 | Apteeus | Compound and method for the treatment of zellweger spectrum disorder |
| CN117643581A (zh) * | 2023-11-29 | 2024-03-05 | 徐州医科大学 | 白藜芦醇在制备激活sirt1基因的药物中的应用 |
| WO2025240286A1 (en) * | 2024-05-14 | 2025-11-20 | Washington State University | Neuron targeted 2-deoxyglucose dendrimer for imaging and treatment of neurological diseases |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2157422T3 (es) | 1995-02-07 | 2001-08-16 | Brusilow Entpr Llc | Trigliceridos y esteres etilicos de acido fenilalcanoico y acido fenilalquenoico utiles en el tratamiento de diversos trastornos. |
| WO2000018394A1 (en) * | 1998-09-28 | 2000-04-06 | The Johns Hopkins University | Adrenoleukodystrophy treatments and drug screening |
| US8148356B2 (en) | 2005-08-24 | 2012-04-03 | Cumberland Pharmaceuticals, Inc. | Acetylcysteine composition and uses therefor |
| TW200817369A (en) * | 2006-05-22 | 2008-04-16 | Elan Pharm Inc | Preparation of polymer conjugates of therapeutic, agricultural and food additive compounds |
| JP5484339B2 (ja) | 2007-10-05 | 2014-05-07 | ウェイン ステート ユニバーシティー | 合成物の持続的な放出のためのデンドリマー |
| PL3133396T3 (pl) | 2008-04-29 | 2019-03-29 | Horizon Therapeutics, Llc | Sposób leczenia z zastosowaniem leków wychwytujących amoniak |
| WO2009142754A1 (en) * | 2008-05-22 | 2009-11-26 | Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dendritic conjugates and methods of use |
| WO2010147831A1 (en) * | 2009-06-15 | 2010-12-23 | Wayne State University | Dendrimer based nanodevices for therapeutic and imaging purposes |
| MY173215A (en) | 2010-07-21 | 2020-01-06 | Cumberland Pharmaceuticals Inc | Acetylcysteine compositions and methods of use thereof |
| DK2760479T3 (en) | 2011-09-30 | 2017-07-17 | Horizon Therapeutics Llc | Nitrogen-removing drug for use in a method of treating a nitrogen retention disorder |
| WO2014178892A1 (en) * | 2013-05-03 | 2014-11-06 | Scanlan Thomas S | Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy |
| EP3019184A4 (en) * | 2013-06-07 | 2017-04-05 | The Administrators of the Tulane Educational Fund | Analogs of pituitary adenylate cyclase-activating polypeptide (pacap) and methods for their use |
| EP3036004B1 (en) | 2013-08-21 | 2022-12-07 | Concordia University | Dendrimer-resveratrol complex |
| AU2015301579B2 (en) * | 2014-08-13 | 2018-08-09 | Kennedy Krieger Institute, Inc. | Dendrimer compositions and use in treatment of neurological and CNS disorders |
-
2016
- 2016-10-31 CA CA3003589A patent/CA3003589C/en active Active
- 2016-10-31 WO PCT/US2016/059697 patent/WO2017075580A1/en not_active Ceased
- 2016-10-31 JP JP2018521617A patent/JP7088473B2/ja active Active
- 2016-10-31 US US15/339,486 patent/US20170119899A1/en not_active Abandoned
- 2016-10-31 AU AU2016343855A patent/AU2016343855B2/en active Active
- 2016-10-31 CN CN201680073817.9A patent/CN108430514B/zh active Active
- 2016-10-31 EP EP16791282.3A patent/EP3368088B1/en active Active
-
2021
- 2021-09-20 US US17/479,400 patent/US20220071923A1/en not_active Abandoned
-
2022
- 2022-05-30 JP JP2022087580A patent/JP2022105767A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3368088C0 (en) | 2023-06-07 |
| AU2016343855A1 (en) | 2018-05-10 |
| CA3003589A1 (en) | 2017-05-04 |
| EP3368088B1 (en) | 2023-06-07 |
| JP2022105767A (ja) | 2022-07-14 |
| JP2018531965A (ja) | 2018-11-01 |
| CN108430514B (zh) | 2023-11-03 |
| WO2017075580A1 (en) | 2017-05-04 |
| US20170119899A1 (en) | 2017-05-04 |
| CN108430514A (zh) | 2018-08-21 |
| AU2016343855B2 (en) | 2019-10-03 |
| EP3368088A1 (en) | 2018-09-05 |
| US20220071923A1 (en) | 2022-03-10 |
| JP7088473B2 (ja) | 2022-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3003589C (en) | Dendrimer compositions and methods for treatment of peroxisomal disorders and leukodystrophies | |
| Aso et al. | Poly (propylene imine) dendrimers with histidine-maltose shell as novel type of nanoparticles for synapse and memory protection | |
| US20250205369A1 (en) | Dendrimer compositions and use in treatment of neurological and cns disorders | |
| He et al. | Development of mannose functionalized dendrimeric nanoparticles for targeted delivery to macrophages: use of this platform to modulate atherosclerosis | |
| Rho et al. | Self-assembled hyaluronic acid nanoparticles: Implications as a nanomedicine for treatment of type 2 diabetes | |
| US20210252153A1 (en) | Selective dendrimer delivery to brain tumors | |
| Cheong et al. | Superparamagnetic iron oxide nanoparticles-loaded chitosan-linoleic acid nanoparticles as an effective hepatocyte-targeted gene delivery system | |
| Haroon et al. | Engineered exosomes mediated targeted delivery of neuroprotective peptide NR2B9c for the treatment of traumatic brain injury | |
| US20220080056A1 (en) | Dendrimer compositions and use in treatment of necrotizing enterocolitis and other gastrointestinal disorders | |
| Uthaman et al. | Inhibiting the cGAS-STING pathway in ulcerative colitis with programmable micelles | |
| KR20220035425A (ko) | 자가면역 질환 치료용 조성물 및 방법 | |
| US20230364244A1 (en) | Dendrimer compositions and methods for drug delivery to injured kidney | |
| CN119053344A (zh) | 用于靶向递送治疗剂至神经元的树枝状聚合物组合物 | |
| US20210322567A1 (en) | Carbohydrate-functionalized nanoparticles and uses thereof | |
| US20230338554A1 (en) | Galactosylated dendrimers for targeted intracellular delivery to hepatocytes | |
| He et al. | ROS-responsive glucosylated nanodisc prodrug for efficient targeted epilepsy therapy | |
| EP4351648A1 (en) | Treatment for down syndrome-related accelerated aging | |
| HK1236118A1 (en) | Dendrimer compositions and use in treatment of neurological and cns disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180427 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241025 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241025 |